- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
TAU Antibody (C-term)Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP2040b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
TAU Antibody (C-term) - Product info | |
| Application | WB, IHC, IF
|
| Primary Accession | P10636 |
| Other Accession | P19332, P10637, P29172 |
| Reactivity | Human |
| Predicted | Bovine, Mouse, Rat |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 78928 Da |
TAU Antibody (C-term) - Additional info | |
| Gene ID 4137 | |
| Other Names MAPT; MAPTL; MTBT1; TAU; Microtubule-associated protein tau; Neurofibrillary tangle protein; Paired helical filament-tau | |
| Target/Specificity This TAU antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 685~714 amino acids from the C-terminal region of human TAU. | |
| Dilution WB~~1:50~100WB~~1:1000 IHC~~1:50~100 IF~~1:10~50 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions TAU Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
TAU Antibody (C-term) - Protein Information | |
| Name MAPT | |
| Synonyms MAPTL, MTBT1, TAU | |
| Function Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization | |
| Cellular Location Cytoplasm, cytosol. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytoskeleton. Cell projection, axon. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components | |
| Tissue Location Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system | |
TAU Antibody (C-term) - Related products
AP1425c: TAU (MAPT) Antibody (S720)
AP2040b: TAU Antibody (C-term)
AP3381a: Phospho-MAPT-S720 Antibody
DC09953: Human MAPT cDNA Clone
LY12097a: MAPT Over-expression Lysate
BP1425c: MAPT Antibody (S720) Blocking Peptide
BP2040b: TAU Antibody (C-term) Blocking Peptide
BP3381a: Phospho-MAPT-S720 Antibody Blocking Peptide
AJ1757a: Tau Antibody Phospho (pS198)
AJ1757b: Tau Antibody Phospho (pS202)
AJ1757c: Tau Antibody Phospho (pS262)
AJ1757d: Tau Antibody Phospho (pS356)
AJ1757e: Tau Antibody Phospho (pS404)
TAU Antibody (C-term) - Application data
-
Western blot analysis of TAU(arrow) using rabbit polyclonal TAU Antibody (Cat.#AP2040b). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the TAU gene (Lane 2) (Origene Technologies).
-
Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.
-
Confocal immunofluorescent analysis of TAU Antibody (C-term)(Cat#AP2040b) with MCF-7 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green).DAPI was used to stain the cell nuclear (blue).
TAU Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The microtubule-associated protein tau (MAPT) gene transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations result in several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
REFERENCES
Yoshiyama, Y., et al., J. Neurosci. 23(33):10662-10671 (2003). Horiguchi, T., et al., Am. J. Pathol. 163(3):1021-1031 (2003). Gamblin, T.C., et al., Proc. Natl. Acad. Sci. U.S.A. 100(17):10032-10037 (2003). Kraemer, B.C., et al., Proc. Natl. Acad. Sci. U.S.A. 100(17):9980-9985 (2003). Yancopoulou, D., et al., J. Neuropathol. Exp. Neurol. 62(8):878-882 (2003).
